Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. (November 2021)

• Record Type: Journal Article
• Authors: Richardson, Noah; Greenway, Steven C.; Bousman, Chad A.
• Is Part Of: Psychiatry research. Volume 305(2021)
• Publication Date: 2021-11
• Subjects: Schizophrenia -- Adverse drug reactions -- Antipsychotic -- Drug therapy -- Drug monitoring -- Drug hypersensitivity -- Rechallenge; Psychiatry -- Periodicals; Psychiatry -- periodicals; Psychiatrie -- Périodiques; 616.89
• DOI: 10.1016/j.psychres.2021.114247
• Languages: English
• ISSNs: 0165-1781

Abstract

Highlights: A concern limiting the use of clozapine in schizophrenia treatment is the risk of rare but potentially fatal myocarditis. Clozapine-induced myocarditis is poorly understood. Predictors for the successful rechallenge of clozapine after a previous episode of myocarditis have not been identified. Increases in troponin or C-reactive protein were present in 87% of reported cases. Case reports to date, have not elucidated robust markers for clozapine rechallenge. Abstract: Clozapine is underutilized due, in part, to concerns about rare but severe adverse drug reactions, including cardiac inflammation and injury (myocarditis). Risk factors for clozapine-induced myocarditis are limited and predictors for the successful rechallenge of clozapine after an episode of myocarditis are even more poorly understood. We conducted a systematic review, in accordance with the PRISMA recommendation, of published case reports to describe demographic and clinical characteristics of patients with clozapine-induced myocarditis and identify potential markers of clozapine rechallenge success. A total of 180 cases from 88 articles were evaluated. Male cases of clozapine-associated myocarditis were more frequently reported than female cases by a ratio of 6:1. Less than half of patients reported the presence of chest pain (35%) or flu-like symptoms (43%) but increases in troponin or C-reactive protein were present in 87% of cases. Clozapine rechallenge was carried out in 34 (2 female) cases, with successful reintroduction in 22 (2 female) cases (64.7%) and one fatality (2.9%). No demographic or clinical markers were significantly associated with rechallenge success after correction for multiple testing. Standardized reporting of clozapine-induced myocarditis cases is needed to facilitate the identification of factors associated with successful rechallenge.